Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action.
Pathogenic variants in breast cancer predisposition genes are associated with poor clinical outcomes but also offer an opportunity for more individualized therapeutic pathways. Given increasing knowledge, improvements in germline genetic testing efficiency, and the availability of novel systemic tar...
| Publicado en: | Current Oncology Vol. 32; no. 6; pp. 290 - 309 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jun2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=186205452&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 186205452 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jun2025 vid: 32 iid: 6 pid: 97109 pub: MDPI artinfo: ui: 186205452 10.3390/curroncol32060290 186205452 ppf: 290 ppct: 19 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action. aug: au: Weber, Evan Carmona-Gonzalez, Carlos A. Boucher, Melanie Eisen, Andrea Laing, Kara Melvin, Jennifer Schrader, Kasmintan A. Sehdev, Sandeep Wong, Stephanie M. Gelmon, Karen A. affil: Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montréal, QC H4A 3J1, Canada sug: ab: Pathogenic variants in breast cancer predisposition genes are associated with poor clinical outcomes but also offer an opportunity for more individualized therapeutic pathways. Given increasing knowledge, improvements in germline genetic testing efficiency, and the availability of novel systemic targeted treatment options, the importance of appropriately identifying patients for testing has never been greater. A pan-Canadian expert working group (EWG) consisting of 10 healthcare professionals (HCPs) was convened to review recent international guidelines for germline genetic testing in breast cancer and develop Canadian recommendations. The group identified four clinical questions to address which patients should undergo testing, what approaches should be used, how patients should be counselled, and what steps are needed for implementation. In response to these questions, the EWG agreed upon 12 recommendations that emphasized broader incorporation of germline genetic testing and more standardized, streamlined testing and counselling approaches. The group also offered multiple suggestions to support effective and equitable implementation across Canada. These recommendations provide guidance for HCPs and represent a call to action for the Canadian government and other organizations to support genetic testing pathways, drug access, and ultimately improved outcomes for patients with breast cancer and their families. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|